Breast Cancer
Conditions
Brief summary
Many breast cancer patients experience psychological distress during their cancer care journey. There are effective treatments for breast cancer patients experiencing distress, such as individual or group therapy, health education, and medication. Unfortunately, clinicians may not be aware of the symptoms of distress in their breast cancer patients, and some breast cancer patients who could benefit from referral to behavioral health specialists are overlooked. New guidelines recommend that all cancer patients be regularly screened for distress. However, there are unanswered questions about the impact of distress screening conducted on a large scale. Few studies have evaluated the impact of distress screening on important outcomes in breast cancer patients, such as patient experience and use of health care services, as compared to the usual care offered by the health care organization. In addition, oncology clinicians may be uncertain about the benefits of large-scale distress screening, and pilot screening programs have not been uniformly successful particularly in the community oncology setting. The overarching goals of this study are to assess the effectiveness of implementing a guideline-recommended distress screening program for newly diagnosed breast cancer patients on improving identification and referral to treatment for highly distressed breast cancer patients, to assess patient-reported outcomes, health services utilization, and implementation outcomes of the program. This study will address two main research questions: 1) Evaluate the effectiveness of a guideline-recommended distress screening program for breast cancer patients in improving identification of distressed patients, initiation and completion of referrals to behavioral health, and patient-reported and utilization outcomes as compared to usual care; 2) Identify the barriers, facilitators, and other implementation-related outcomes related to distress screening in the community oncology setting. Please note: This study did not require a DSMB, as it falls under the exception for low-risk behavioral studies.
Detailed description
Background and Study Aims: Breast cancer patients are at risk for physical and psychosocial harms. Among the most highly prevalent psychosocial issues in breast cancer patients is psychological distress. Distress is defined and assessed as psychiatric morbidity or prevalence of psychiatric disorders, particularly anxiety and depression. It is estimated that 40-50% of women diagnosed with early stage breast cancer will experience distress in the year following diagnosis. There is a rich literature on the persistent negative effects of distress in breast cancer patients, including associations with decreased physical and social functioning, increased symptom burden, higher utilization of inpatient and emergency services, and poor quality of life. Psychological distress can also adversely affect individual work productivity, and contributes to the rising costs of cancer care. Recent guidelines from the American Society of Clinical Oncology (ASCO) and others recommend routine distress screening for breast cancer patients, recognizing the availability of effective treatments for psychological distress. Unfortunately distress remains under-detected and undertreated in breast cancer patients and rates of adherence to ASCO and other guidelines is very low. Low rates of screening might be explained in part by limited evidence of effectiveness: while efficacy of distress screening has been demonstrated in small-scale trials at academic centers, typically showing increases in number of referrals to psychosocial services, evidence supporting the effectiveness of large scale distress screening programs under routine practice conditions is limited. It is currently unknown if distress screening of breast cancer patients will improve identification of distressed patients or referrals to behavioral health services in non-academic settings. In addition, extant efficacy studies generally fail to measure key impacts and outcomes desired from distress screening, such as patient-reported outcomes (e.g., distress management, satisfaction) and changes in health care utilization (e.g., changes in emergency department use). Implementation-related factors and outcomes have also been largely overlooked in prior research (e.g., clinician acceptability, fidelity of delivery), leaving serious gaps in the understanding of barriers to adoption of distress screening programs and gaps in the knowledge needed to facilitate large-scale, routine implementation of screening. The overarching goal of this study is to implement and evaluate a guideline-based distress screening program for newly diagnosed breast cancer patients, measuring its effectiveness and impacts on key outcomes and examining barriers and facilitators to routine adoption. There is a critical need for translational research to assess the effectiveness of distress screening programs in improving (a) identification of distress, (b) referral for services, (c) outcomes for breast cancer patients in real-world oncology settings, and in understanding implementation barriers and facilitators. Without evidence of effectiveness, it is unlikely that clinical and operational health system leaders will invest in distress screening programs, potentially leading to serious adverse consequences. This proposed translational research is crucial in order to bridge the gap between academic studies and non-academic, community oncology practice, where the majority of breast cancer patients are treated. In addition, gaining insight and understanding into barriers and facilitators to implementation of distress screening programs is critically important. The objectives are to assess the effectiveness of the recommended screening program from the joint task force of the American Psychosocial Oncology Society, Association of Oncology Social Work, and Oncology Nursing Society on improving identification and referral to treatment for highly distressed breast cancer patients within an integrated health care system, and to assess patient-reported outcomes, health services utilization, and implementation outcomes of the program. Specific Aims: Aim 1: Evaluate the effectiveness of a guideline-recommended distress screening program for breast cancer patients in improving identification of distressed patients, initiation and completion of referrals to behavioral health, and patient-reported and utilization outcomes as compared to usual care within Kaiser Permanente Southern California (KPSC), using a pragmatic cluster randomized control trial design at six medical centers. Aim 2: Identify patient-, clinician-, and system-level barriers and facilitators to implementation of the program, and assess stakeholder-perceived acceptability, fidelity, and achievements of the program. Study Methods The setting for this research is Kaiser Permanente Southern California, a large, integrated health care system with 14 medical centers serving a highly diverse population of over 4 million members. The investigators will use a novel hybrid effectiveness-implementation study design that allows for dual study of the clinical effectiveness and implementation-related factors to address the need for evidence in both areas. This study will employ mixed methods, collecting both qualitative and quantitative data as appropriate to address the study aims. To evaluate effectiveness, this study will use a cluster randomized control trial (RCT) design, clustered at the medical center level, and will implement the program at the intervention sites and offering screening to all newly diagnosed breast cancer patients. To evaluate the effectiveness of the program, the investigators will collect structured data from the KPSC electronic record (referral initiation/completion, use of health services) and patient-reported data (functioning, symptom management). Existing work from a pilot primary care-based distress screening program will be leveraged for this research, demonstrating the feasibility of this study. Implementation outcomes will be assessed with qualitative and survey data. Knowledge gained from this research will be used to inform the continued development and implementation of systematic distress screening programs for breast cancer patients, and will enrich the evidence base by providing critical information on relevant patient- and system-level outcomes. These results will have an impact on the quality of life and quality of care for these patients, and will directly influence distress screening program adoption, scale-up, and spread, making this work highly relevant to breast cancer patients throughout California and across the nation.
Interventions
A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
Sponsors
Study design
Eligibility
Inclusion criteria
* Newly diagnosed with initial breast cancer, any stage, any histology type * Kaiser Permanente member for at least 100 days during study period
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Offered and Screened for Distress | Patients assessed during initial consult - e.g. 1 day during 60 min consult | \# of newly diagnosed breast cancer patients offered and screened with the Patient Health Questionnaire 9 at their initial consult |
| Number of Participants Offered an Appropriate Referral | Patients assessed during initial consult - e.g. 1 day during 60 min consult | For patients who had screening done in Oncology, appropriate action for those with a medium/high PHQ-9 is a referral to social work, psychiatry, depression care management. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Breast Cancer Prevention Trial (BCPT) Symptom Checklist | 12 months | Self-reported measure of physical symptoms in the past 4 weeks; scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; 4=extremely. Higher scores indicate greater symptom burden. Sub-scales include Hot Flashes, Nausea, Bladder Control, Vaginal Problems, Musculoskelatal Pain, Cognitive Problems, Weight Problems, and Arm Problems. |
| Number of Patients With Primary Care Visit | 18 months | Between group comparison of number of visits to primary care. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage. |
| Number of Patients With Oncology Visit | 18 months | Between group comparison of number of visits to oncology. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage. |
| Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | 12 months | Self-reported for physical well-being; social family well-being; emotional well-being; functional well-being; and additional concerns over the past 7 days; scale: 0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much; responses indicate symptoms/concerns in the past 7 days. The higher the score, the better the outcome. To derive a FACT-B total score, score range 0-148. The subscales include: (1) Physical Well-Being, score range 0-28; (2) Social/Family Well-Being, score range 0-28; (3) Emotional Well-Being, score range 0-24; (4) Functional well-being, score range 0-28; (5) Breast Cancer Subscale, score range 0-40. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Utilizing Behavioral Health Services | 18 months | Between group comparison of number of visits with behavioral health providers. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage. |
| Number of Participants Utilizing Emergency and Urgent Care Services | 18 months | Between group comparison of number of visits to emergency and urgent care services. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Distress Screening Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
Distress screening: A brief depression and anxiety screening instrument, the Patient Health Questionnaire (PHQ), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm. The PHQ starts with a 2-item screen, and branches to the full screening instrument as needed. | 744 |
| No Screening Newly diagnosed breast cancer patients will experience usual care. | 692 |
| Total | 1,436 |
Baseline characteristics
| Characteristic | Distress Screening | No Screening | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 319 Participants | 311 Participants | 630 Participants |
| Age, Categorical Between 18 and 65 years | 425 Participants | 381 Participants | 806 Participants |
| Age, Continuous | 61.1 years STANDARD_DEVIATION 12.35 | 62 years STANDARD_DEVIATION 13.34 | 61.5 years STANDARD_DEVIATION 12.84 |
| Cancer Stage Missing | 37 Participants | 21 Participants | 58 Participants |
| Cancer Stage Stage 0 | 32 Participants | 27 Participants | 59 Participants |
| Cancer Stage Stage I | 145 Participants | 106 Participants | 251 Participants |
| Cancer Stage Stage II | 236 Participants | 234 Participants | 470 Participants |
| Cancer Stage Stage III | 236 Participants | 219 Participants | 455 Participants |
| Cancer Stage Stage IV | 58 Participants | 85 Participants | 143 Participants |
| Charlson Comorbidity Score | 2.2 units on a scale STANDARD_DEVIATION 2.75 | 2.1 units on a scale STANDARD_DEVIATION 2.62 | 2.2 units on a scale STANDARD_DEVIATION 2.69 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 204 Participants | 172 Participants | 376 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 483 Participants | 476 Participants | 959 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 57 Participants | 44 Participants | 101 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 5 Participants | 7 Participants | 12 Participants |
| Race (NIH/OMB) Asian | 151 Participants | 113 Participants | 264 Participants |
| Race (NIH/OMB) Black or African American | 106 Participants | 143 Participants | 249 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 6 Participants | 7 Participants | 13 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 73 Participants | 50 Participants | 123 Participants |
| Race (NIH/OMB) White | 401 Participants | 370 Participants | 771 Participants |
| Region of Enrollment United States | 744 Participants | 692 Participants | 1436 Participants |
| Sex: Female, Male Female | 740 Participants | 689 Participants | 1429 Participants |
| Sex: Female, Male Male | 4 Participants | 3 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 25 / 744 | 16 / 692 |
| other Total, other adverse events | 0 / 744 | 0 / 692 |
| serious Total, serious adverse events | 0 / 744 | 0 / 692 |
Outcome results
Number of Participants Offered an Appropriate Referral
For patients who had screening done in Oncology, appropriate action for those with a medium/high PHQ-9 is a referral to social work, psychiatry, depression care management.
Time frame: Patients assessed during initial consult - e.g. 1 day during 60 min consult
Population: Patients who completed PHQ-9 screening in Oncology with med/high score
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Distress Screening | Number of Participants Offered an Appropriate Referral | 51 Participants |
| No Screening | Number of Participants Offered an Appropriate Referral | 0 Participants |
Number of Participants Offered and Screened for Distress
\# of newly diagnosed breast cancer patients offered and screened with the Patient Health Questionnaire 9 at their initial consult
Time frame: Patients assessed during initial consult - e.g. 1 day during 60 min consult
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Distress Screening | Number of Participants Offered and Screened for Distress | 596 Participants |
| No Screening | Number of Participants Offered and Screened for Distress | 3 Participants |
Breast Cancer Prevention Trial (BCPT) Symptom Checklist
Self-reported measure of physical symptoms in the past 4 weeks; scale: 0=not at all; 1=slightly; 2=moderately; 3=quite a bit; 4=extremely. Higher scores indicate greater symptom burden. Sub-scales include Hot Flashes, Nausea, Bladder Control, Vaginal Problems, Musculoskelatal Pain, Cognitive Problems, Weight Problems, and Arm Problems.
Time frame: 12 months
Population: Number of participants analyzed varies across rows for 3-, 6- and 12-month surveys because not all patients completed all surveys and/or answered all questions in a survey.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Vaginal/Sex Problems Sub-Scale | 0.7 units on a scale | Standard Deviation 1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Suvey 3 month Bladder Control Sub-Scale | 0.6 units on a scale | Standard Deviation 0.9 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Musculoskeletal Pain Sub-Scale | 1.5 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Weight Problems Sub-Scale | 1.1 units on a scale | Standard Deviation 1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Cognitive Problems Sub-Scale | 1.0 units on a scale | Standard Deviation 1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 Month Total Score | 0.9 units on a scale | Standard Deviation 0.6 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Weight Problems Sub-Scale | 1.1 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Arm Problems Sub-Scale | 0.6 units on a scale | Standard Deviation 0.8 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Arm Problems Sub-Scale | 0.5 units on a scale | Standard Deviation 0.7 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Vaginal/Sex Problems Sub-Scale | 0.6 units on a scale | Standard Deviation 1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Total Score | 0.9 units on a scale | Standard Deviation 0.6 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Suvey 6 month Total Score | 0.9 units on a scale | Standard Deviation 0.7 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Hot Flashes Sub-Scale | 1.1 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Nausea Sub-Scale | 0.4 units on a scale | Standard Deviation 0.7 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Nausea Sub-Scale | 0.2 units on a scale | Standard Deviation 0.4 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Hot Flashes Sub-Scale | 1.2 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Bladder Control Sub-Scale | 0.7 units on a scale | Standard Deviation 0.9 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Musculoskeletal Pain Sub-Scale | 1.5 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Vaginal/Sex Problem Sub-Scale | 0.8 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Musculoskeletal Pain Sub-Scal | 1.7 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Nausea Sub-Scale | 0.2 units on a scale | Standard Deviation 0.4 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Cognitive Problems Sub-Scale | 1.0 units on a scale | Standard Deviation 1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Hot Flashes Sub-Scale | 1.2 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Weight Problems Sub-Scale | 1.0 units on a scale | Standard Deviation 1.1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Bladder Control Sub-Scale | 0.7 units on a scale | Standard Deviation 1 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Arm Problems Sub-Scale | 0.5 units on a scale | Standard Deviation 0.8 |
| Distress Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Suvey 3 month Cognitive Problems Sub-Scale | 1.2 units on a scale | Standard Deviation 1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Arm Problems Sub-Scale | 0.5 units on a scale | Standard Deviation 0.7 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 Month Total Score | 1.0 units on a scale | Standard Deviation 0.7 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Hot Flashes Sub-Scale | 1.2 units on a scale | Standard Deviation 1.2 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Nausea Sub-Scale | 0.5 units on a scale | Standard Deviation 0.8 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Suvey 3 month Bladder Control Sub-Scale | 0.7 units on a scale | Standard Deviation 1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Vaginal/Sex Problems Sub-Scale | 0.8 units on a scale | Standard Deviation 1.1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Musculoskeletal Pain Sub-Scale | 1.5 units on a scale | Standard Deviation 1.1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Suvey 3 month Cognitive Problems Sub-Scale | 1.2 units on a scale | Standard Deviation 1.1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Weight Problems Sub-Scale | 1.2 units on a scale | Standard Deviation 1.2 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 3 month Arm Problems Sub-Scale | 0.5 units on a scale | Standard Deviation 0.9 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Suvey 6 month Total Score | 0.9 units on a scale | Standard Deviation 0.6 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Hot Flashes Sub-Scale | 1.1 units on a scale | Standard Deviation 1.2 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Nausea Sub-Scale | 0.3 units on a scale | Standard Deviation 0.5 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Bladder Control Sub-Scale | 0.6 units on a scale | Standard Deviation 0.9 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Vaginal/Sex Problems Sub-Scale | 0.8 units on a scale | Standard Deviation 1.1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Musculoskeletal Pain Sub-Scale | 1.4 units on a scale | Standard Deviation 1.2 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Cognitive Problems Sub-Scale | 1.0 units on a scale | Standard Deviation 1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Weight Problems Sub-Scale | 1.2 units on a scale | Standard Deviation 1.1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 6 month Arm Problems Sub-Scale | 0.5 units on a scale | Standard Deviation 0.8 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Total Score | 0.9 units on a scale | Standard Deviation 0.6 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Hot Flashes Sub-Scale | 1.0 units on a scale | Standard Deviation 1.1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Nausea Sub-Scale | 0.3 units on a scale | Standard Deviation 0.6 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Bladder Control Sub-Scale | 0.7 units on a scale | Standard Deviation 0.9 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Musculoskeletal Pain Sub-Scal | 1.5 units on a scale | Standard Deviation 1.1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Cognitive Problems Sub-Scale | 1.1 units on a scale | Standard Deviation 1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Weight Problems Sub-Scale | 1.1 units on a scale | Standard Deviation 1 |
| No Screening | Breast Cancer Prevention Trial (BCPT) Symptom Checklist | BCPT Survey 12 month Vaginal/Sex Problem Sub-Scale | 0.9 units on a scale | Standard Deviation 1.2 |
Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B)
Self-reported for physical well-being; social family well-being; emotional well-being; functional well-being; and additional concerns over the past 7 days; scale: 0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much; responses indicate symptoms/concerns in the past 7 days. The higher the score, the better the outcome. To derive a FACT-B total score, score range 0-148. The subscales include: (1) Physical Well-Being, score range 0-28; (2) Social/Family Well-Being, score range 0-28; (3) Emotional Well-Being, score range 0-24; (4) Functional well-being, score range 0-28; (5) Breast Cancer Subscale, score range 0-40.
Time frame: 12 months
Population: Patients who completed at least one survey item in Fact-B at the 3, 6 and/or 12 month survey. The number of participants analyzed for the total scores and sub-scale scores at 3-, 6- and 12 months varies, because not all patients responded to all surveys or answered all of the questions in a survey.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Total Score | 104.5 units on a scale | Standard Deviation 22.1 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Physical Well-Being Subscale | 20.8 units on a scale | Standard Deviation 6.2 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3 month Social/Family Well-Being Subscale | 21.2 units on a scale | Standard Deviation 6.2 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3 month Emotional Well-Being Subscale | 18.3 units on a scale | Standard Deviation 4.3 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Functional Well-Being Subscale | 18.3 units on a scale | Standard Deviation 6.7 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Breast Cancer Subscale | 26.5 units on a scale | Standard Deviation 6.8 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Total Score | 108.1 units on a scale | Standard Deviation 22.3 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Physical Well-Being Subscale | 22.3 units on a scale | Standard Deviation 5.9 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Social/Family Well-Being Subscale | 20.5 units on a scale | Standard Deviation 6.2 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Emotional Well-Being Subscale | 18.5 units on a scale | Standard Deviation 4.3 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Functional Well-Being Subscale | 19.2 units on a scale | Standard Deviation 6.2 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Breast Cancer Subscale | 27.0 units on a scale | Standard Deviation 6.9 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Total Score | 109.1 units on a scale | Standard Deviation 22.9 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Physical Well-Being Subscale | 22.1 units on a scale | Standard Deviation 5.6 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Social/Family Well-Being Subscale | 20.7 units on a scale | Standard Deviation 6.1 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Emotional Subscale | 18.8 units on a scale | Standard Deviation 3.9 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Functional Well-Being | 19.9 units on a scale | Standard Deviation 6.3 |
| Distress Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Breast Cancer Subscale | 27.1 units on a scale | Standard Deviation 6.9 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Physical Well-Being Subscale | 22.3 units on a scale | Standard Deviation 5.5 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Total Score | 104.6 units on a scale | Standard Deviation 23 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Emotional Well-Being Subscale | 18.0 units on a scale | Standard Deviation 4.4 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Physical Well-Being Subscale | 20.5 units on a scale | Standard Deviation 6.5 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Breast Cancer Subscale | 26.9 units on a scale | Standard Deviation 6.8 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3 month Social/Family Well-Being Subscale | 21.4 units on a scale | Standard Deviation 5.8 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Functional Well-Being Subscale | 18.5 units on a scale | Standard Deviation 6.4 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3 month Emotional Well-Being Subscale | 18.3 units on a scale | Standard Deviation 4.4 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Social/Family Well-Being Subscale | 20.9 units on a scale | Standard Deviation 6 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Functional Well-Being Subscale | 18.1 units on a scale | Standard Deviation 6.6 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Breast Cancer Subscale | 25.8 units on a scale | Standard Deviation 7.5 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 3-month Breast Cancer Subscale | 26.4 units on a scale | Standard Deviation 6.9 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Functional Well-Being | 19.9 units on a scale | Standard Deviation 5.9 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Total Score | 105.3 units on a scale | Standard Deviation 21.9 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Total Score | 108.3 units on a scale | Standard Deviation 22.4 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Physical Well-Being Subscale | 21.9 units on a scale | Standard Deviation 5.4 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 12 month Emotional Subscale | 18.6 units on a scale | Standard Deviation 4.4 |
| No Screening | Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B) | Fact-B 6 month Social/Family Well-Being Subscale | 21.3 units on a scale | Standard Deviation 5.3 |
Number of Patients With Oncology Visit
Between group comparison of number of visits to oncology. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage.
Time frame: 18 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Distress Screening | Number of Patients With Oncology Visit | 728 Participants |
| No Screening | Number of Patients With Oncology Visit | 683 Participants |
Number of Patients With Primary Care Visit
Between group comparison of number of visits to primary care. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage.
Time frame: 18 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Distress Screening | Number of Patients With Primary Care Visit | 648 Participants |
| No Screening | Number of Patients With Primary Care Visit | 616 Participants |
Number of Participants Utilizing Behavioral Health Services
Between group comparison of number of visits with behavioral health providers. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage.
Time frame: 18 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Distress Screening | Number of Participants Utilizing Behavioral Health Services | 287 Participants |
| No Screening | Number of Participants Utilizing Behavioral Health Services | 247 Participants |
Number of Participants Utilizing Emergency and Urgent Care Services
Between group comparison of number of visits to emergency and urgent care services. Restricted to patients with at least 100 days of follow-up. Covariates included in multivariable models were age, Charlson's comorbidity index, race/ethnicity, marital status, and cancer stage.
Time frame: 18 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Distress Screening | Number of Participants Utilizing Emergency and Urgent Care Services | ED Visits | 248 Participants |
| Distress Screening | Number of Participants Utilizing Emergency and Urgent Care Services | Urgent Care Visits | 269 Participants |
| No Screening | Number of Participants Utilizing Emergency and Urgent Care Services | ED Visits | 213 Participants |
| No Screening | Number of Participants Utilizing Emergency and Urgent Care Services | Urgent Care Visits | 279 Participants |